Large registry studies have shown superior disease-free survival (DFS) with matched sibling donor (MSD) allogeneic hematopoietic cell transplantation (allo-HCT) over chemotherapy alone for patients with B-precursor acute lymphoblastic leukemia (ALL) and a late BM relapse. As most of these patients will not have an MSD, the decision to pursue an unrelated allo-HCT in second remission (CR2) or await a future relapse and perform HCT in third remission (CR3) continues to be debated. Between 1990 and 2006, 41 children with relapsed B-precursor ALL received a myeloablative allo-HCT at the University of Minnesota. Graft sources consisted of matched related donor (n ¼ 11), matched unrelated donor (n ¼ 9), and unrelated umbilical cord blood (n ¼ 21). Before allo-HCT, 15 patients had an early relapse (o36 months from diagnosis) and 26 had an initial late relapse (X36 months from diagnosis). In all, 30 patients (73%) were in CR2 and 11 were in CR3 (27%) at time of allo-HCT. Five year OS/DFS were similar for patients with an early or late marrow relapse, but there was inferior DFS among late-relapse patients transplanted in CR3 compared with CR2 (30% vs 75%, P ¼ 0.04). These results suggest that allo-HCT should be pursued in children after a first marrow relapse, rather than waiting for subsequent recurrence. Bone Marrow Transplantation (2011) 46, 950-955; 
Introduction
Although acute lymphoblastic leukemia (ALL) continues to be the most common pediatric cancer diagnosed in North America, the introduction of risk adapted and intensive upfront therapy has resulted in more than 80% of children with ALL becoming long-term survivors. 1, 2 Despite these encouraging results for what was once a uniformly fatal disease, 20-25% of children with ALL relapse, making relapsed ALL the fifth most common pediatric cancer in the United States. [3] [4] [5] [6] As the majority of children who relapse with leukemia eventually succumb to their disease, identifying optimal therapy for relapsed patients continues to be a challenge. [7] [8] [9] The outcomes of children with B-precursor ALL who experience a BM relapse depend on a number of factors, including the timing of the relapse. When treated with chemotherapy alone, patients with B-precursor ALL with an early BM relapse (o36 months from diagnosis) have significantly inferior outcomes when compared with those with late marrow relapses (X36 months from diagnosis). [10] [11] [12] [13] [14] As a result, these patients often proceed to allogeneic hematopoietic cell transplantation (allo-HCT) with the best available donor once a second remission (CR2) is achieved. Results from IBMTR/POG registries have reported 5-year disease-free survival (DFS) for children with late BM relapses of 32 ± 6% when treated with chemotherapy alone (n ¼ 76) and 53±7% when treated with chemotherapy and a matched sibling donor (MSD) allo-HCT (n ¼ 76) (Po0.001). 15 Traditionally, it has been suggested that patients with a late relapse and no matched related donor (MRD) available continue with chemotherapy. This recommendation has been based on relatively equivalent survival between patients receiving chemotherapy vs an unrelated donor (URD) transplant as well as the higher morbidity and TRM associated with allo-HCT. Recently, DFS in children and adults with relapsed ALL in CR2 has been shown to be similar between URDs and MRD, which is a tribute to the decreasing TRM in the URD setting from improvements in human leukocyte antigen (HLA) typing and supportive care. 10, 16 Thus, the decision to proceed to URD allo-HCT or continue with standard chemotherapy after a late relapse should continue to be reassessed.
In this retrospective analysis, we report our single institution experience of 41 relapsed B-precursor ALL patients who experienced an early or late BM relapse, showing the advantage of allo-HCT as consolidative therapy, regardless of donor source and timing of the relapse, when performed before subsequent relapse.
Patients and methods
Between 1990 and 2006, 41 pediatric patients (ages 2-21 years) received a myeloablative allo-HCT for relapsed B-precursor ALL at the University of Minnesota. Of these 41 patients, 15 (37%) had an early BM relapse and 26 (63%) had a late BM relapse before allo-HCT (Table 1) . For the purpose of this analysis, we defined early BM relapse as occurring less than 36 months from the initial diagnosis of leukemia and a late BM relapse as occurring at 36 months or greater from diagnosis. BM relapse includes isolated BM or combined (BM and central nervous system, skin or testis) relapses. For patients transplanted in third remission (CR3), assignment to early or late groups was based on their first relapse. All patients and/or guardians underwent informed consent before transplant on University of Minnesota IRB approved treatment protocols.
The median age at time of allo-HCT was 9 (range 2-21) years with the median time from initial diagnosis to HCT 45.9 (range 15.7-146.4) months. The median time from first relapse to HCT was 4 (range 2-69) months. In all, 27 patients (66%) were male. The majority of patients were transplanted during the years 2000 to 2006 (n ¼ 27). All patients received conditioning with CY (120 mg/kg) and TBI (1320-1375 cGy). In addition to Cy/TBI, fludarabine (25 mg/m 2 /day) was added in seven patients and etoposide (30 mg/kg) in six patients. GVHD prophylaxis was CSAbased in all but two patients who received a T-cell-depleted graft. Before 2000, more patients received URD BM grafts and MTX for GVHD prophylaxis whereas after 2000, the majority of patients received umbilical cord blood transplants incorporating fludarabine in the conditioning regimen and mycophenolate mofetil for GVHD prophylaxis.
Graft Three patients in the early relapse group (20%) had a combined BM relapse [BM/central nervous system (2), BM/skin (1)] compared with 11 (42%) of the late-relapse patients [BM/central nervous system (8) , BM/testes (3)]. At the time of allo-HCT, 30 patients (73%) were in CR2 and 11 were in CR3 (27%).
There were no patients in this analysis who carried either the mixed lineage leukemia (11q23) or bcr-abl (Ph chromosome) translocation. Among the 15 early-relapse patients, three had hyperdiploidy (450 chromosomes) and one severe hypodiploidy (o44 chromosomes) compared with six hyperdiploid and two patients with an ETV6/RUNX1 translocation among the 26 late-relapse patients.
As the majority of the early BM relapse patients were in CR2 (n ¼ 14) compared with CR3 (n ¼ 1) at the time of allo-HCT and the decision to pursue allo-HCT for these earlyrelapse patients is more clearly accepted, the analysis focused on comparing the impact of remission status (CR2 vs CR3) in B-precursor ALL patients with a late BM relapse.
Statistical methods
Data on patient characteristics, post-transplant complications and outcomes were prospectively collected by the Biostatistical Support Group at the University of Minnesota using standard collection procedures. Patient and disease characteristics were summarized using descriptive statistics. Early and late BM relapse patients were compared using non-parametric Wilcoxon test for continuous factors and Pearson's chi-square test for categorical factors. The primary endpoint was OS. Other endpoints included DFS, TRM, risk of relapse, acute GVHD (aGVHD) and chronic GVHD (cGVHD). Cumulative incidence was used to estimate relapse, TRM, aGVHD and cGVHD. 17 Kaplan-Meier was used to estimate OS and DFS. 18 Statistical comparison of OS and DFS between groups was completed by the Log-Rank test. The proportional hazards model of Fine and Gray was used to assess the independent factors on relapse, TRM, aGVHD and cGVHD. 19 Factors included in multivariate analysis were: CR status, recipient CMV status, transplant cell source, transplant year, time from diagnosis to transplant, time 
Results

Early marrow relapse outcomes
The median follow up for the 15 patients with an early BM relapse was 68 (range 25-131) months. Four patients (27%) developed grade 2-4 aGVHD with 3 of these 4 patients having grade 3-4 aGVHD. All patients who developed aGVHD received an URD (2 MUD, 2 UCB). cGVHD (extensive) was reported in 2 patients (13%), both of whom received a MUD donor and had prior aGVHD. In univariate analysis, the 5-year OS and DFS were 53% and 47% ( Figure 1a) . The cumulative incidence of relapse at 3-years was 53% in this group (Figure 1b) . There was no significant difference in either OS (P ¼ 0.80) or DFS (P ¼ 0.43) based on graft source (MRD vs. MUD/UCB) and there were no deaths attributed to TRM among these early-relapse patients.
Late marrow relapse outcomes
The median follow-up for patients with a late BM relapse was 67 (range 38-127) months. aGVHD (grade 2-4) occurred in seven patients (28%), five who received URD grafts (two UCB and three MUD) and two related donor grafts (one MRD and one MSD). cGVHD (all extensive) was reported in three patients (12%) who received MUD (n ¼ 2) and MRD (n ¼ 1). In univariate analysis, the 5-year OS and DFS was 62 and 58% ( Figure 1a) . The cumulative incidence of relapse at 3-years was 19% in this group (Figure 1b) . There was no significant difference in OS (P ¼ 0.89) or DFS (P ¼ 0.89) based on graft source (MRD vs MUD/UCB). TRM at 6 months was 12% (n ¼ 3) with the causes of mortality being infection (n ¼ 2) and secondary late graft failure (n ¼ 1).
Of the 26 late marrow relapse patients, 10 (38%) were transplanted in CR3 and 16 (62%) in CR2. The decision whether or not to perform allo-HCT in CR3 vs CR2 was decided by the referring physicians. There was no significant difference in the incidence of aGVHD based on CR status (CR3: 30% vs CR2: 25%; P ¼ 0.78) but there was significantly more cGVHD in CR3 patients compared with those in CR2 (30% vs 0%, P ¼ 0.01). The incidence of TRM at 6 months was similar between patients in CR3 vs CR2 (10% vs 13%, P ¼ 0.84). In univariate analysis, the 5-year OS and DFS for late marrow relapse patients in CR3 were 40 and 30% compared with 75 and 75% for those in CR2 (P ¼ 0.09 and P ¼ 0.04, respectively) ( Figure 2a) . The cumulative incidence of relapse at 3-years was 30% for CR3 patients vs 13% for those transplanted in CR2 (P ¼ 0.24) (Figure 2b) . In multivariate analysis, there was no significant difference in either OS or DFS for the late marrow relapse patients based on CR status but there Late relapse CR2 patients (n =16)
Late relapse CR3 patients (n =10) Figure 2 (a) Cumulative incidence of disease-free survival. Cumulative incidence of disease-free survival for the two late relapse groups (CR2 vs C R3) at 5-years was 75 and 30%, respectively (P ¼ 0.04). (b) Cumulative incidence of relapse. Cumulative incidence of relapse for these two late relapse groups (CR2 vs CR3) at 3-years was 13 and 30%, respectively (P ¼ 0.24).
was a greater risk of relapse for patients transplanted in CR3 (RR 5.18; 95% CI 1.32-20.35, P ¼ 0.02) ( Table 2) .
Discussion
Although most children with ALL can be cured of their disease with current pediatric chemotherapy-based protocols, more than 500 children will relapse each year. [3] [4] [5] [6] When treated with chemotherapy alone, patients with B-precursor ALL and an early BM relapse have significantly inferior outcomes compared with those who have late relapses, 7, 9, 12, 14, 15 likely reflecting differences in the biology of various subtypes of ALL. As a result, patients with early marrow relapses are typically treated with allo-HCT using the best available donor. [10] [11] [12] [13] [14] The optimal treatment for children with a BM relapse X36 months after diagnosis is uncertain as results comparing chemotherapy re-treatment to allo-HCT are mixed. [12] [13] [14] [15] In this retrospective analysis, we report our single institution experience with allo-HCT for 41 pediatric B-precursor ALL patients who experienced either an early or late BM relapse. In univariate analysis, there was inferior DFS for late-relapse patients transplanted in CR3 compared with CR2. Although OS and DFS were comparable in multivariate analysis, patients with a late marrow relapse transplanted in CR3 were more likely to have disease recurrence.
The transplant outcomes we report for early marrow relapse patients using either related or unrelated stem cell sources compare favorably to MSD allo-HCT. Although we have a relatively small cohort of early-relapse patients (n ¼ 15), the DFS at 5-years of 47% is similar to both the Berlin-Frankfurt-Munster (n ¼ 51) and Australian (n ¼ 13) experience using MSD, reporting 8-year DFS of 52±8% and 54%, respectively. 9, 12 In the much larger IBMTR study (n ¼ 179) of MSD allo-HCT for children with early marrow relapse B-precursor ALL, the reported 5-year DFS was lower at 35 ± 4%. 15 The DFS following allo-HCT in this study was superior to the historical outcomes for early marrow relapse following chemotherapy alone (47 vs 10-26%). 14, 15, [20] [21] [22] Overall, with improvements in current high resolution HLA-typing and supportive care measures, HCT outcomes using alternative donors (MUD and UCB) have now approached those of MSD HCT. 10, 16 Thus, allo-HCT with the best available donor is currently recommended for children with B-precursor ALL who suffer an early marrow relapse.
Studies of children with B-precursor ALL with late marrow relapse treated with chemotherapy alone compared with allo-HCT have typically found improved outcomes when MSD transplant is performed. Both the IBMTR (n ¼ 76) and MSKCC (n ¼ 26) reported allo-HCT using MSD having significantly greater DFS at 5-years (53 ± 7% and 81 ± 10%, respectively) compared with chemotherapy alone (32±6% and 37±3%; Po0.001 and Po0.01, respectively). 14, 15 Although other investigators have reported trends toward improved outcomes for late marrow relapse patients using MSD allo-HCT compared with chemotherapy alone, 9, 12, 13, 20 none of these studies have compared outcomes in late marrow relapse patients based on CR status (CR2 vs CR3).
There is very limited data comparing outcomes of late BM relapse B-precursor ALL patients based on CR status (CR2 vs CR3) to guide the management once a relapse occurs. The Berlin-Frankfurt-Munster relapse study group evaluated outcomes of patients with B-precursor and T-cell ALL in CR2 (n ¼ 136) vs CR3 (n ¼ 33) treated with MRD allo-HCT, asking whether delaying allo-HCT until a further relapse occurred (that is, 4CR2) was acceptable. 23 Patients with a late BM relapse (X6 months after completing previous therapy) comprised 41 and 42% of the CR2 and CR3 groups, respectively. Although the 6-year EFS for the late-relapse patients was similar between groups (CR2: 53% vs CR3: 61%; P ¼ 0.84) the toxic death rate was 30% for CR3 patients compared with 13% for the CR2 group (no P value reported). The authors concluded that foregoing allo-HCT for late relapse ALL patients might be a reasonable approach, particularly when no MRD is available. However, as this was an older analysis with allo-HCT performed between the years 1983-1995 and significant improvements in transplant have since been made further decreasing toxic deaths, particularly in the unrelated allo-HCT setting, revisiting the question whether CR status impacts HCT outcomes was warranted. 24 One potential rationale in foregoing allo-HCT for a patient with a late marrow relapse is to reserve the HCT for a future relapse. Although our study includes a relatively small cohort of patients with late marrow relapse, our analysis shows that CR status at the time of HCT provides insight into the utility of allo-HCT in multiple relapsed children. Of the 26 late marrow relapse B-precursor ALL patients, 40% had suffered a second relapse and were in a CR3 at time of allo-HCT. There was no significant difference in TRM between these two CR groups, perhaps reflecting improvements in pre-and post-allo-HCT care. Inferior outcomes for both DFS (in the univariate) and relapse (in the multivariate analyses) were observed when allo-HCT was reserved for a second relapse (that is, performed in a subsequent CR3). Moreover, certainly some patients in CR2 who experience a subsequent relapse may not be able to be cured with either chemotherapy alone or allo-HCT. There was a striking difference in 5-year DFS comparing CR2 and CR3 late marrow relapse patients, favoring those receiving allo-HCT after their first relapse in CR2 (70 vs 25%) in our univariate model. However, this lost significance in the multivariate analyses, possibly because of our relatively small number of patients. In multivariate analysis of patients with a late BM relapse, there was a fivefold greater risk of further relapse in patients receiving allo-HCT in CR3 compared with CR2. Given the outcomes for B-precursor ALL patients with a late BM relapse when allo-HCT is pursued in CR2 (compared with CR3), our data suggest that for patients in CR2, unrelated allo-HCT is a viable option and prospective clinical trials directly comparing URD transplantation to chemotherapy for patients with late relapsed CR2 are needed. The Children's Oncology Group is currently investigating this question in patients with BPrecursor ALL and late BM relapse in the trial AALL0433. In this study, patients who have an identified HLAmatched family donor are eligible for consolidation with allo-HCT after initial three blocks of induction/consolidation therapy. These patients will be prospectively compared with patients who do not receive allo-HCT and continue with intensified consolidation and maintenance chemotherapy. If the results of this study indeed confirm a survival advantage for MSD allo-HCT (compared with intensified chemotherapy alone), the recommendation of best available donor allo-HCT among pediatric BMT centers may follow based on recent studies demonstrating equivalent DFS using related donor and URDs, 10, 16 alternatively, direct comparisons may be necessary.
In conclusion, in this cohort of early and late BM relapse B-precursor ALL patients, we report a relatively high 5-year EFS rate when using allo-HCT as consolidation, regardless of donor source. Patients with initial relapse X36 months from diagnosis who are transplanted in CR3 have a considerably inferior DFS compared with late-relapse patients transplanted in CR2. This finding brings into question the utility of HCT for patients in second or greater relapse and argues for considering HCT for any B-precursor ALL patient after their first marrow relapse.
